Marilena C.
- Country
- Romania
- Department
- Neurology
Research Overview
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Remibrutinib in Generalized Myasthenia Gravis Patients with Stable Standard of Care
- A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis
Data & Insights
Has run more than one trial at 5 of 62 partner sites.
Specializations
Neuromuscular Disorders
The investigator specializes in the study of generalized Myasthenia Gravis (gMG), focusing on evaluating innovative therapeutic approaches for this challenging autoimmune condition.
- Neuromuscular Junction Disorders
- Autoimmune Neurology
- Daily Living Activities Assessment
Particular emphasis is placed on evaluating treatment efficacy through standardized assessment tools such as the Myasthenia Gravis Activity of Daily Living (MG-ADL) scale.
Treatment Innovation
The investigator conducts research in targeted therapeutic approaches for neuromuscular conditions, with specific interest in novel pharmaceutical interventions for autoimmune disorders.
- Therapeutic Assessment
- Clinical Efficacy Evaluation
- Safety Monitoring
Research activities focus on evaluating both immediate therapeutic benefits and long-term treatment outcomes in neuromuscular conditions.
Clinical Assessment
Expertise extends to standardized clinical evaluation methods for measuring therapeutic outcomes in neuromuscular disorders.
- Patient Function Assessment
- Treatment Response Monitoring
- Quality of Life Evaluation
The investigator employs comprehensive assessment approaches to evaluate treatment efficacy and patient improvement in daily activities.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.